Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials

Diabetes Research and Clinical Practice

Volumn 130, Issue , 2017, Pages 53-60

  Monami, Matteo ^a   Nreu, Besmir ^a   Zannoni, Stefania ^a   Lualdi, Carlotta ^a   Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Ketoacidosis; Meta analysis; Randomized clinical trials; Serious adverse events; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

ACARBOSE; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; IPRAGLIFLOZIN; LINAGLIPTIN; LUSEOGLIFLOZIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; DIABETIC KETOACIDOSIS; HUMAN; INCIDENCE; KETOACIDOSIS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS;

DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85019751779     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.04.017     Document Type: Article

References (21)

1. Hemmingsen, B., Krogh, J., Metzendorf, M.I., Richter, B., Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev, 2016 Epub-ahead of print.
2. Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
3. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
4. Wu, J.H., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
5. Burke, K.R., et al. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy 37 (2017), 187–194.
6. Food and Drug Administration. Safety Alert on Canagliflozin, issued on Oct 10th, 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm. Last accessed on 3rd August, 2016.
7. Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
8. Qiu, H., Novikov, A., Vallon, V., Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev, 2017 [Epub ahead of print].
9. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
10. Bode, B., Stenlöf, K., Sullivan, D., Fung, A., Usiskin, K., Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013:41 (1995), 72–84.
11. https://clinicaltrials.gov/ct2/show/NCT01032629?term=nct01032629&rank=1. Last accessed on 3rd August, 2016.
12. Lavalle-González, F.J., Eliaschewitz, F.G., Cerdas, S., Chacon Mdel, P., Tong, C., Alba, M., Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin 32 (2016), 427–439.
13. Wilding, J.P., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 16 (2014), 124–136.
14. Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
15. Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
16. Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U.C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38 (2015), 420–428.
17. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Last accessed on 3rd August, 2016.
18. Taylor, S.I., Blau, J.E., Rother, K.I., SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100 (2015), 2849–2852.
19. Tang, H., Li, D., Wang, T., Zhai, S., Song, Y., Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 39 (2016), e123–e124.
20. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Last accessed on 3rd August, 2016.
21. Rosenstock, G., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.